Biocept - Buy the negativity. The revenue doesn't mind.
Biocept has the best-in-breed liquid biopsy testing in the Immuno-Oncology space. Market cap is 70 million, but it's going to be several billion in a few years if they don't get bought out first.
Revenue in the second quarter ended 6/30/2016 increased 8 fold to 663,000 from 77,000 last year. This revenue only included half of June for their commerical launch of its PD-L1 protein expression test in mid-June. Frankly, I’m surprised that they didn’t burn through a lot more cash and issue a lot more shares considering their disastrous dilution last year. Their expenses didn’t go up as much as I was expecting either, and they’re sitting on $3.8 million in cash.
Revenue in the second quarter ended 6/30/2016 increased 8 fold to 663,000 from 77,000 last year. This revenue only included half of June for their commerical launch of its PD-L1 protein expression test in mid-June. Frankly, I’m surprised that they didn’t burn through a lot more cash and issue a lot more shares considering their disastrous dilution last year. Their expenses didn’t go up as much as I was expecting either, and they’re sitting on $3.8 million in cash.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.